Key Takeaways from ACC.25: Advances in Cardiovascular Science
Key Takeaways from ACC.25: Advances in Cardiovascular Science
1. Innovations in Transcatheter Aortic Valve Replacement (TAVR) :
• The JenaValve Trilogy Transcatheter Heart Valve System demonstrated promising outcomes for patients with symptomatic, severe aortic regurgitation who are at high surgical risk(Unlike current TAVR valves designed to treat aortic stenosis).
The ALIGN-AR trial reported a technical success rate of 95%, with significant improvements in patients’ functional status and quality of life over a one-year follow-up period. 
2. Long-Term Efficacy of TAVR in Low-Risk Patients:
• The Evolut Low Risk trial presented five-year data indicating that TAVR with the Medtronic Evolut system is non-inferior to surgical aortic valve replacement (SAVR) concerning all-cause mortality or disabling stroke in patients with severe aortic stenosis at low surgical risk. These findings support the durability and effectiveness of TAVR as a viable alternative to surgery in this patient population. 
These advancements highlight the ongoing evolution of TAVR technologies and their expanding role in treating a broader spectrum of patients with aortic valve diseases(TAVR currently make up more than 80% of the aortic valve replacement procedures in the U.S).